Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Caimi

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Eclinicalmedicine|March 21, 2025
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Blood Advances|August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 StudyAlex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021Andrew D Zelenetz, Leo I Gordon, Julie E Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 9, 2025
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Blood Advances|October 21, 2022
Postibrutinib relapse outcomes for patients with marginal zone lymphomaNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Eclinicalmedicine|March 21, 2025
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Blood Advances|August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 StudyAlex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Blood Advances|September 21, 2021
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignanciesMatthew S Davids, Owen A O'Connor, Wojciech Jurczak, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2021
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021Andrew D Zelenetz, Leo I Gordon, Julie E Chang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 9, 2025
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 7, 2023
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023Andrew D Zelenetz, Leo I Gordon, Jeremy S Abramson, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Blood Advances|October 21, 2022
Postibrutinib relapse outcomes for patients with marginal zone lymphomaNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Pageof 12